meta_pixel
Tapesearch Logo
Log in
The Dividend Cafe

Covid and Markets - Tuesday September 15

The Dividend Cafe

The Dividend Cafe - The Bahnsen Group

Macro Economics, Monetary Policy, Dividend Growth Investing, Retirement Planning, Wealth Management, Investing, Business, Estate Planning

4.9572 Ratings

🗓️ 15 September 2020

⏱️ 10 minutes

🧾️ Download transcript

Summary

COVID Health Information • The seven-day average of 34.7k new daily cases is down 48.4% from the July 22 peak.

• The BioNTech/Pfizer vaccine project has said they believe it is “likely” their vaccine will be distributable before the end of the year. They obviously cannot predict what the FDA approval process will look like but there seems to be a lot of confidence in the direction of their vaccine trials. They recently expanded their trial pool from 30,000 to 44,000.

• Madrid’s hospitalizations through the so-called “second wave” of Spain are 1/7th (14%) that of what they were in the spring. I hate being so redundant with you but often the news itself is redundant. The cases are less severe, the people are healthier, the treatments are better, and so forth and so on

• New cases in Denmark have tripled, whereas in Sweden they have barely moved. As for what could possibly be causing this dynamic, I guess I would refer you to:all the media reports covering this prior issues of COVID & Markets.

• JP Morgan has determined that productivity does, indeed, fall for employees working from home. In other news, I have determined that the sun is hot.

• The University of Pittsburgh School of Medicine has a promising development you may want to read more about.

Links mentioned in this episode: DividendCafe.com TheBahnsenGroup.com

Transcript

Click on a timestamp to play from that location

0:00.0

Welcome to the Dividend Cafe weekly market commentary focused on dividends in your portfolio and dividends in your understanding of economic life.

0:12.8

Hello and welcome to today's COVID and markets podcast brought to you by the Dividend Cafe of the Bonson Group.

0:20.3

We have a short but sweet one today.

0:22.7

I have been in Connecticut all day to day and client meetings,

0:26.3

and there's a few things I want to be able to cover,

0:28.7

but it's not quite the same normal amount of data and information we might have.

0:34.6

Look, the seven-day average of new cases, 34,000 plus change right now, as far as new daily

0:44.8

cases, that's the seven-day average of new daily cases, is down 48.5% from the July 22nd peak.

0:55.3

So that case growth that so many want to obsess on continues to drop

1:00.3

with astronomically higher testing,

1:04.3

even as the positivity right now has dropped back into the 4 to 5 percent range. I don't have Tuesdays activity rate yet as I'm

1:17.0

recording. Maybe I'll get it by the time I'm done recording, but yesterday's Monday was only

1:22.3

4%. So we're dealing with just very, very low positives or declining.

1:29.5

I will point out a couple things quickly before I go to the market.

1:35.4

That Buy-InTech Pfizer vaccine project, many believe to be in the lead for final approvals,

1:43.8

has said that they believe it is likely their vaccine will be

1:48.0

distributable before the end of the year, before the end of the calendar year.

1:52.7

They obviously can't predict what the FDA's approval process will look like, but for them

1:57.4

to say that, it seems to be indicating a lot of confidence in the direction of their clinical trials.

2:06.1

They did expand their trial pool from 30,000 people in the U.S. to 44,000.

2:12.9

So there's a lot of things going in the right direction there.

2:17.8

We'll continue to monitor that and all the other vaccine cases.

...

Please login to see the full transcript.

Disclaimer: The podcast and artwork embedded on this page are from The Dividend Cafe - The Bahnsen Group, and are the property of its owner and not affiliated with or endorsed by Tapesearch.

Generated transcripts are the property of The Dividend Cafe - The Bahnsen Group and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.

Copyright © Tapesearch 2026.